Inventor · disambiguated record
Alfred P. Spada
Also filed as: SPADA ALFRED P
55 granted patents·10 pending applications·5,652 citations·filing 1986–2023
99Inventor score
Files withRHONE POULENC RORER PHARMA24AVENTIS PHARMA INC11AVENTIS PHARM PROD INC7RORER PHARMACEUTICAL CORP5CONATUS PHARMACEUTICALS INC4
Top patents by PatentIndex Score
65 records- 0199US6528526B1Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2000·Granted Mar 4, 2003·305 cites·37 claims
- 0299US6524347B1Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2000·Granted Feb 25, 2003·307 cites·11 claims
- 0399US6180632B1Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARM PROD INC·Filed 1998·Granted Jan 30, 2001·395 cites·79 claims
- 0499US6057320ABis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseAVENTIS PHARM PROD INC·Filed 1997·Granted May 2, 2000·148 cites·13 claims
- 0599USRE36256EBis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1997·Granted Jul 20, 1999·183 cites·20 claims
- 0699US5646153ABis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1995·Granted Jul 8, 1997·259 cites·18 claims
- 0799US5480883ABis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1993·Granted Jan 2, 1996·383 cites·20 claims
- 0899US5302606AStyryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1991·Granted Apr 12, 1994·284 cites·12 claims
- 0998US6482834B2Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2001·Granted Nov 19, 2002·254 cites·50 claims
- 1098US6245760B1Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARM PROD INC·Filed 1998·Granted Jun 12, 2001·257 cites·57 claims
- 1198US5710158AAryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1994·Granted Jan 20, 1998·339 cites·14 claims
- 1298US5561134ACompounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesRHONE POULENC RORER PHARMA·Filed 1994·Granted Oct 1, 1996·143 cites·26 claims
- 1398US5364862ACompounds having antihypertensive and anti-ischemic propertiesRHONE POULENC RORER PHARMA·Filed 1992·Granted Nov 15, 1994·141 cites·18 claims
- 1497US6159978AQuinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARM PROD INC·Filed 1998·Granted Dec 12, 2000·203 cites·36 claims
- 1597US5721237AProtein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation propertiesRHONE POULENC RORER PHARMA·Filed 1995·Granted Feb 24, 1998·245 cites·13 claims
- 1697US5714493AAryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1994·Granted Feb 3, 1998·176 cites·1 claims
- 1797US5656643ABis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1995·Granted Aug 12, 1997·258 cites·4 claims
- 1897US5409930ABis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1992·Granted Apr 25, 1995·314 cites·13 claims
- 1997US4822794APyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their usesRORER PHARMACEUTICAL CORP·Filed 1987·Granted Apr 18, 1989·63 cites·10 claims
- 2095US5795889ABis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1995·Granted Aug 18, 1998·59 cites·17 claims
- 2193US6645969B1Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseAVENTIS PHARMA INC·Filed 1995·Granted Nov 11, 2003·74 cites·12 claims
- 2293USRE37650EAryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinaseAVENTIS PHARMACETICAL PRODUCTS·Filed 1994·Granted Apr 9, 2002·88 cites·5 claims
- 2393US6323227B1Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amidesAVENTIS PHARM PROD INC·Filed 1999·Granted Nov 27, 2001·76 cites·61 claims
- 2493US4866074ANaphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their usesRORER PHARMACEUTICAL CORP·Filed 1988·Granted Sep 12, 1989·42 cites·11 claims
- 2592US5736554ACompounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesRHONE POULENC RORER PHARMA·Filed 1995·Granted Apr 7, 1998·102 cites·8 claims
- 2691US6846815B2Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2003·Granted Jan 25, 2005·28 cites·18 claims
- 2790US6080767ASubstituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amidesAVENTIS PHARM PROD INC·Filed 1997·Granted Jun 27, 2000·100 cites·43 claims
- 2890US5656655AStyryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinaseRHONE-POULENC INC·Filed 1995·Granted Aug 12, 1997·50 cites·10 claims
- 2990US5612353ASubstituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compoundsRHONE POULENC RORER PHARMA·Filed 1995·Granted Mar 18, 1997·59 cites·12 claims
- 3087US6559313B2Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic propertiesAVENTIS PHARMA GMBH·Filed 2002·Granted May 6, 2003·21 cites·2 claims
- 3186US5652366ADI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereofRHONE POULENC RORER PHARMA·Filed 1995·Granted Jul 29, 1997·93 cites·2 claims
- 3284US6696434B2Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2002·Granted Feb 24, 2004·14 cites·62 claims
- 3382US6376472B1Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic propertiesAVENTIS PHARMA INC·Filed 1998·Granted Apr 23, 2002·24 cites·15 claims
- 3480US6034093ASubstituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compoundsRHONE POULENC RORER PHARMA·Filed 1998·Granted Mar 7, 2000·28 cites·30 claims
- 3576US5677329AStyryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1995·Granted Oct 14, 1997·15 cites·16 claims
- 3674US5731315ASubstituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compoundsRHONE POULENC RORER PHARMA·Filed 1996·Granted Mar 24, 1998·20 cites·44 claims
- 3774US4859672APyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinoneRORER PHARMACEUTICAL CORP·Filed 1986·Granted Aug 22, 1989·11 cites·17 claims
- 3873US5002944ACompounds having cardiotonic activityRHONE POULENC RORER PHARMA·Filed 1989·Granted Mar 26, 1991·10 cites·5 claims
- 3972US5418245AStyryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinaseRHONE POULENC RORER INT·Filed 1994·Granted May 23, 1995·12 cites·18 claims
- 4071US6852712B2Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2003·Granted Feb 8, 2005·3 cites·13 claims
- 4171US5476851APyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinaseRHONE POULENC RORER PHARMA·Filed 1994·Granted Dec 19, 1995·25 cites·24 claims
- 4269US6821962B2Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2003·Granted Nov 23, 2004·2 cites·37 claims
- 4368US5597837AMethod and composition for treating psoriasis with styryl-substituted pyridyl compoundsRH & E CIR O & EE NE POULENC R·Filed 1994·Granted Jan 28, 1997·8 cites·6 claims
- 4467US7612075B2Substituted oxoazaheterocyclyl compoundsAVENTIS PHARMA INC·Filed 2003·Granted Nov 3, 2009·3 cites·15 claims
- 4564US6140504ASubstituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amidesAVENTIS PHARM PROD INC·Filed 2000·Granted Oct 31, 2000·2 cites·2 claims
- 4661US12071412B2Caspase inhibitors and methods of use thereofNOBO MEDICINE INC·Filed 2023·Granted Aug 27, 2024·0 cites·3 claims
- 4759US7550597B2Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinasesAVENTIS PHARMA INC·Filed 2005·Granted Jun 23, 2009·0 cites·6 claims
- 4859US5556990APolyarylcarbamoylaza- and -carbamoylalkanedioic acidsRHONE POULENC RORER PHARMA·Filed 1994·Granted Sep 17, 1996·8 cites·19 claims
- 4958US5217982ACompounds having antihypertensive propertiesRHONE POULENC RORER PHARMA·Filed 1990·Granted Jun 8, 1993·10 cites·12 claims
- 5058US2008207605A1Combination therapy for the treatment of liver diseasesSPADA ALFRED P·Filed 2008·Application pending·0 cites
Showing the top 50 of 65 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →